Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Medical Device

Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China

Fineline Cube Jan 23, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...

Company Medical Device

Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device

Fineline Cube Jan 23, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...

Company

LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou

Fineline Cube Jan 23, 2024

LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of...

Company Deals Digital Policy / Regulatory

Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative

Fineline Cube Jan 23, 2024

The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd,...

Company Deals

Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment

Fineline Cube Jan 23, 2024

Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...

Company Drug

HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jan 23, 2024

China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...

Policy / Regulatory

Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan

Fineline Cube Jan 23, 2024

The General Office of the CPC Central Committee and State Council has released the “Implementation...

Company Drug

AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment

Fineline Cube Jan 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...

Company Drug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Jan 23, 2024

Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...

Policy / Regulatory

NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions

Fineline Cube Jan 23, 2024

The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...

Company Deals

Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine

Fineline Cube Jan 23, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...

Company Deals

Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements

Fineline Cube Jan 23, 2024

Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...

Company Deals

Digital Precision Medicine Secures Over $28 Million in Series C Financing

Fineline Cube Jan 22, 2024

Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...

Company Drug

NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin

Fineline Cube Jan 22, 2024

The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...

Company Drug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

Fineline Cube Jan 22, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...

Company Drug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

Fineline Cube Jan 22, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...

Company Drug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

Fineline Cube Jan 22, 2024

The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...

Policy / Regulatory

Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth

Fineline Cube Jan 22, 2024

Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...

Company

Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches

Fineline Cube Jan 22, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...

Company Drug

Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis

Fineline Cube Jan 22, 2024

Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...

Posts pagination

1 … 348 349 350 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.